Longitude Capital has promoted Sandip K. Agarwala to managing director. Prior to joining Longitude in 2013, Agarwala worked at Auven Therapeutics where he served as a vice president.
MENLO PARK, Calif. and GREENWICH, Conn., May 20, 2015 /PRNewswire/ — Longitude Capital, a private investment firm that focuses on venture growth investments in drug development and medical technology, today announced the promotion of Sandip K. Agarwala to Managing Director.
Mr. Agarwala joined Longitude in 2013 and focuses on structured investments in both biotechnology and medical device companies. He was responsible for the creation of the firm’s royalty investment vehicle, CrownWheel Partners, and its associated infrastructure. Mr. Agarwala led the firm’s investments in multiple royalty transactions, assembling a diversified portfolio of healthcare revenue interests. Looking forward, he will continue to lead Longitude’s royalty investment strategy.
“Sandip has contributed significantly to our investment platform at Longitude Capital,” said Longitude Managing Director and co-Founder, Patrick Enright. “He has helped us build an important new capability in the area of royalty monetizations and structured transactions that we believe will continue to be a significant deployment area for our funds.”
Prior to joining Longitude, Mr. Agarwala was a Vice President with Auven Therapeutics, a private equity firm that invests in late-development stage biopharmaceutical projects and companies. Mr. Agarwala’s professional experience also includes roles with Healthcare Royalty Partners, Paul Capital Partners, the Boston Consulting Group and The Frankel Group. He holds an M.B.A. in Finance and Health Care Management from the Wharton School of Business at the University of Pennsylvania, and a B.S.E. in Systems Science and Engineering from the University of Pennsylvania.
About Longitude Capital
Longitude Capital (www.longitudecapital.com) is a private investment firm that focuses on venture growth investments in drug development and medical technology. The firm builds balanced portfolios of mid-stage to commercial-stage companies with clinically de-risked assets that are likely to achieve key value-creating milestones within three to five years. Besides traditional venture capital investments, Longitude’s investment team also proactively searches for “special situations”, such as spin-outs, recapitalizations, PIPEs, royalty monetizations and structured transactions, across both privately-held and publicly-traded companies.
Founded in 2006, Longitude Capital consists of ten investment professionals and operates bi-coastally with offices in Menlo Park, CA and Greenwich, CT. Recent investments made by the team include Allergen Research Corporation, Amarin Corporation, AqueSys, California CryoBank, Cadence Pharmaceuticals, Civitas Therapeutics, Collegium Pharmaceutical, Corcept Therapeutics, Esperion Therapeutics, Jazz Pharmaceuticals, NxStage Medical, Precision Dermatology, Twelve and Venus Concept. Longitude Capital has over $700 million in assets under management, and most recently raised $385 million for its second fund, Longitude Venture Partners II, L.P., in 2012.